Juan W Valle
Overview
Explore the profile of Juan W Valle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
239
Citations
11333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Knox J, McNamara M, Bazin I, Oh D, Zubkov O, Breder V, et al.
J Hepatol
. 2025 Feb;
PMID: 39978598
Background And Aims: The previous first-line standard of care for advanced biliary tract cancer (aBTC), gemcitabine/cisplatin, had modest efficacy. NUC-1031 is a phosphoramidate modification of gemcitabine. We report final analyses...
2.
Moir J, Radhakrishna G, Valle J, Al-Adhami A, Albazaz R
BMJ Oncol
. 2025 Jan;
2(1):e000055.
PMID: 39886489
Objective: Appropriate staging of pancreatic cancer is essential to ensure patients are offered all treatment options. This multispecialty national collaborative consensus project aimed to develop a succinct radiological reporting template,...
3.
Ellis H, Braconi C, Valle J, Bardeesy N
Am J Pathol
. 2024 Dec;
195(3):437-452.
PMID: 39730074
Cholangiocarcinoma is an aggressive bile duct malignancy with heterogeneous genomic features. Although most patients receive standard-of-care chemotherapy/immunotherapy, genomic changes that can be targeted with established or emerging therapeutics are common....
4.
Palmer D, Jackson R, Springfeld C, Ghaneh P, Rawcliffe C, Halloran C, et al.
J Clin Oncol
. 2024 Dec;
:JCO2401118.
PMID: 39637340
Purpose: The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survival...
5.
Pieterman C, Grozinsky-Glasberg S, OToole D, Howe J, Ambrosini V, Belli S, et al.
J Neuroendocrinol
. 2024 Nov;
37(1):e13468.
PMID: 39587981
Multiple Endocrine Neoplasia type 1 (MEN1) Clinical Practice Guidelines (2012) are predominantly based on expert opinion due to limited available evidence at the time, leaving room for interpretation and variation...
6.
Ligero M, Hernando J, Delgado E, Garcia-Ruiz A, Merino-Casabiel X, Ibrahim T, et al.
BJC Rep
. 2024 Nov;
1(1):9.
PMID: 39516643
Background: More accurate predictive biomarkers in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are needed. This study aims to investigate radiomics-based tumour phenotypes as a surrogate biomarker of the tumour vasculature...
7.
Palepu J, Endo I, Chaudhari V, Murthy G, Chaudhuri S, Adam R, et al.
HPB (Oxford)
. 2024 Aug;
26(11):1311-1326.
PMID: 39191539
Background: The Delphi consensus study was carried out under the auspices of the International and Asia-Pacific Hepato-Pancreato-Biliary Associations (IHPBA-APHPBA) to develop practice guidelines for management of gallbladder cancer (GBC) globally....
8.
Khan S, Rushbrook S, Kendall T, Zen Y, Albazaz R, Manoharan P, et al.
Gut
. 2024 Aug;
74(3):504-505.
PMID: 39160057
No abstract available.
9.
van Keulen A, Buettner S, Olthof P, Klumpen H, Erdmann J, Izquierdo-Sanchez L, et al.
Ann Surg Oncol
. 2024 Jun;
31(10):6495-6503.
PMID: 38896226
Background: Resection of perihilar cholangiocarcinoma (pCCA) is a complex procedure with a high risk of postoperative mortality and early disease recurrence. The objective of this study was to compare patient...
10.
Goyal L, Meric-Bernstam F, Hollebecque A, Valle J, Morizane C, Karasic T, et al.
Future Oncol
. 2024 Jun;
20(36):2811-2822.
PMID: 38884254
What Is This Summary About?: This summary describes the results from a phase 2 study called FOENIXCCA2. The study evaluated treatment with futibatinib in people with a rare form of...